Abstract
Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have